Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMIG

- PMLiVE

Industry frustrated by late warning on ‘no deal’ Brexit disruption

Dover and Folkestone could have 6 months of disruption

- PMLiVE

UK’s genomics leadership attracts IQVIA investment, regardless of Brexit

Invests in Genomics England alliance, plus clinical trials expansion

- PMLiVE

UK life sciences gets some Brexit relief with £1.3bn sector deal

Highlights commitments from Roche, IQVIA, Celgene and Autolus

- PMLiVE

Triple defeat puts May’s Brexit deal up against the wall

Prospects of a no-deal Brexit seems to loom ever larger

Live from Singapore: Oncology in APAC – Evaluating the opportunity for novel therapies

Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST

Research Partnership

- PMLiVE

UK pharma Brexit pessimism deepens, as govt admits sector could be among worst hit

Political gridlock fuels fears ahead of 11 Dec vote

- PMLiVE

EU27 backs Brexit terms – now the hard part starts for May

House of Commons looks set to oppose the deal

Comment: the new UK pricing deal – welcome news, but lessons to be learned

Leslie Galloway, chairman of EMIG reflects on the new UK government-pharma industry pricing agreement

- PMLiVE

As Brexit looms, UK medicines agency head Hudson announces departure

Search for successor must start in early 2019

- PMLiVE

UK and EU’s future relationship ‘must protect patients’

UK coalition concerned about regulation, data sharing, infectious disease controls

- PMLiVE

Brexit deal looks dead in the water – what now?

Fears of no deal Brexit return after MPs make opposition clear

- PMLiVE

Healthcare sector bullish despite political uncertainty

Targeted and gene therapies rated as major advances ahead of Jefferies conference in London

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links